title: Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection?
authors.forename: Clara
authors.initials: C
authors.lastname: De Simone
authors.forename: Giacomo
authors.initials: G
authors.lastname: Caldarola
authors.forename: Marina
authors.initials: M
authors.lastname: Castriota
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Salerno
authors.forename: Franco
authors.initials: F
authors.lastname: Citterio
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010391:Pemphigoid, Bullous / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus; D008775:Methylprednisolone